{"id":"levo-leucovorin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea and vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levo-leucovorin (the pharmacologically active form of folinic acid) acts as a reduced folate cofactor that potentiates 5-fluorouracil (5-FU) activity in cancer cells. By providing the necessary one-carbon unit, it increases the binding affinity of 5-FU metabolites to thymidylate synthase, thereby enhancing inhibition of DNA synthesis and increasing cytotoxicity. This mechanism is particularly important in colorectal cancer and other solid tumors where 5-FU is a standard chemotherapy agent.","oneSentence":"Levo-leucovorin is the active L-isomer of leucovorin that enhances the cytotoxic effects of fluorouracil by stabilizing the ternary complex between fluorodeoxymonophosphate, thymidylate synthase, and the cofactor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:52.267Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (in combination with 5-fluorouracil)"},{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT05379595","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-29","conditions":"Advanced or Metastatic Colorectal Cancer","enrollment":225},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT07333053","phase":"NA","title":"Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer","status":"RECRUITING","sponsor":"Quanda Liu","startDate":"2026-03-31","conditions":"Unresectable Colorectal Cancer","enrollment":30},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT05959356","phase":"PHASE2","title":"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-09","conditions":"Metastatic Colorectal Cancer","enrollment":198},{"nctId":"NCT05052099","phase":"PHASE1, PHASE2","title":"Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2021-10-22","conditions":"Biliary Tract Cancer","enrollment":20},{"nctId":"NCT05678257","phase":"PHASE2","title":"A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer","status":"TERMINATED","sponsor":"NuCana plc","startDate":"2023-04-18","conditions":"Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma","enrollment":180},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT07124884","phase":"PHASE2","title":"5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-08-31","conditions":"Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer","enrollment":300},{"nctId":"NCT06793917","phase":"PHASE3","title":"Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-06-07","conditions":"Gastric Cancer","enrollment":269},{"nctId":"NCT05714553","phase":"PHASE1, PHASE2","title":"NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours","status":"TERMINATED","sponsor":"NuCana plc","startDate":"2023-03-08","conditions":"Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant","enrollment":19},{"nctId":"NCT07070713","phase":"PHASE2","title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-07-30","conditions":"Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy","enrollment":44},{"nctId":"NCT04554836","phase":"PHASE2","title":"MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab","status":"COMPLETED","sponsor":"TheraOp","startDate":"2020-12-29","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum","enrollment":6},{"nctId":"NCT06988852","phase":"PHASE2","title":"FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-05-01","conditions":"Colorectal Liver Metastasis (CRLM)","enrollment":300},{"nctId":"NCT02839915","phase":"PHASE2","title":"Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Southwest Autism Research & Resource Center","startDate":"2020-08-13","conditions":"Autism Spectrum Disorder","enrollment":56},{"nctId":"NCT03597581","phase":"PHASE1","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Inspirna, Inc.","startDate":"2018-06-05","conditions":"Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer","enrollment":89},{"nctId":"NCT06521866","phase":"PHASE2","title":"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-01","conditions":"Advanced Colorectal Carcinoma, Immunotherapy","enrollment":208},{"nctId":"NCT05319639","phase":"PHASE1, PHASE2","title":"Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2023-02-16","conditions":"Gastric Cancer Stage IV","enrollment":51},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT06609863","phase":"NA","title":"dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-01","conditions":"Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab","enrollment":27},{"nctId":"NCT02578368","phase":"PHASE3","title":"Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2016-02","conditions":"Gastric Cancer","enrollment":183},{"nctId":"NCT03635021","phase":"PHASE3","title":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2018-10-15","conditions":"Colorectal Cancer","enrollment":419},{"nctId":"NCT06616259","phase":"PHASE3","title":"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study","status":"NOT_YET_RECRUITING","sponsor":"Meng Qiu","startDate":"2024-09-26","conditions":"Colorectal Cancer (CRC), Capecitabine, Cetuximab","enrollment":452},{"nctId":"NCT06061276","phase":"NA","title":"bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-05-20","conditions":"Liver Diseases, Hepatocellular Carcinoma, Immunotherapy","enrollment":40},{"nctId":"NCT06070636","phase":"NA","title":"bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-05-20","conditions":"Liver Diseases, Hepatocellular Carcinoma, Immunotherapy","enrollment":30},{"nctId":"NCT04931420","phase":"PHASE2","title":"Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-05-19","conditions":"Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma","enrollment":""},{"nctId":"NCT06509126","phase":"PHASE3","title":"Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2024-06-12","conditions":"Colorectal Cancer Stage IV","enrollment":500},{"nctId":"NCT05022030","phase":"PHASE2","title":"First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2021-07-21","conditions":"Colo-rectal Cancer, Capecitabine, Cetuximab","enrollment":150},{"nctId":"NCT03694522","phase":"PHASE2","title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Five Prime Therapeutics, Inc.","startDate":"2018-09-14","conditions":"Gastric Cancer","enrollment":155},{"nctId":"NCT03343301","phase":"PHASE1","title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Five Prime Therapeutics, Inc.","startDate":"2017-11-30","conditions":"Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic, Gastric Cancer","enrollment":12},{"nctId":"NCT06226857","phase":"PHASE3","title":"Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"City Clinical Oncology Hospital No 1","startDate":"2024-01-17","conditions":"Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation","enrollment":355},{"nctId":"NCT06197438","phase":"PHASE2","title":"Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2024-01-01","conditions":"Gastric Cancer","enrollment":36},{"nctId":"NCT04310176","phase":"PHASE2","title":"Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2019-05-24","conditions":"Ras-mutated Metastatic Colorectal Cancer","enrollment":200},{"nctId":"NCT04169347","phase":"PHASE2","title":"FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer","status":"UNKNOWN","sponsor":"Criterium, Inc.","startDate":"2019-12-02","conditions":"Colorectal Cancer Metastatic","enrollment":27},{"nctId":"NCT05263219","phase":"PHASE3","title":"DEB-TACE+HAIC vs. HAIC for Large HCC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2022-02-10","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":230},{"nctId":"NCT02973685","phase":"PHASE3","title":"HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-10-01","conditions":"HepatoCellular Carcinoma","enrollment":315},{"nctId":"NCT01718873","phase":"PHASE3","title":"Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2012-05","conditions":"Colorectal Cancer","enrollment":230},{"nctId":"NCT04389086","phase":"PHASE3","title":"Induction Chemotherapy for Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Catharina Ziekenhuis Eindhoven","startDate":"2020-11-13","conditions":"Recurrent Rectal Cancer","enrollment":364},{"nctId":"NCT01327612","phase":"PHASE2","title":"Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-03-03","conditions":"Advanced Solid Tumors, Carcinoid, Colorectal Cancer","enrollment":12},{"nctId":"NCT02972541","phase":"NA","title":"Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2016-09-30","conditions":"Colorectal Cancer, Neoadjuvant Chemotherapy, Stent","enrollment":248},{"nctId":"NCT03688230","phase":"PHASE2","title":"Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.","status":"WITHDRAWN","sponsor":"SFJ Pharmaceuticals X, LTD.","startDate":"2019-04","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT03899870","phase":"","title":"Factors Predicting Recurrence in Rectal Cancer After Surgery","status":"COMPLETED","sponsor":"ammar houssem","startDate":"2000-01-01","conditions":"Rectal Cancer, Rectal Adenocarcinoma","enrollment":188},{"nctId":"NCT03671252","phase":"PHASE3","title":"Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-11-16","conditions":"Rectal Cancer","enrollment":776},{"nctId":"NCT02195180","phase":"PHASE2","title":"Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma","status":"COMPLETED","sponsor":"ERYtech Pharma","startDate":"2014-07","conditions":"Pancreatic Adenocarcinoma Metastatic","enrollment":141},{"nctId":"NCT03048123","phase":"PHASE2","title":"HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-10-01","conditions":"Hepatocellular Carcinoma","enrollment":79},{"nctId":"NCT02960061","phase":"PHASE3","title":"Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2016-11","conditions":"Survival","enrollment":640},{"nctId":"NCT00457691","phase":"PHASE3","title":"Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-06","conditions":"Metastatic Colorectal Cancer","enrollment":768},{"nctId":"NCT00865709","phase":"PHASE2","title":"Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03","conditions":"Metastatic Colorectal Cancer","enrollment":198},{"nctId":"NCT01533740","phase":"","title":"Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"2012-03","conditions":"Metastatic Colorectal Cancer","enrollment":31},{"nctId":"NCT00609622","phase":"PHASE2","title":"Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-04","conditions":"Colorectal Neoplasms","enrollment":191}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"CHILLS"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"BAND NEUTROPHIL COUNT INCREASED"},{"count":1,"reaction":"ELECTROLYTE IMBALANCE"},{"count":1,"reaction":"HEART RATE INCREASED"},{"count":1,"reaction":"LEUKOPENIA"},{"count":1,"reaction":"PETECHIAE"},{"count":1,"reaction":"PYREXIA"},{"count":1,"reaction":"THROMBOCYTOPENIA"},{"count":1,"reaction":"TREMOR"}],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Levo-Leucovorin","genericName":"Levo-Leucovorin","companyName":"Fujian Cancer Hospital","companyId":"fujian-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levo-leucovorin is the active L-isomer of leucovorin that enhances the cytotoxic effects of fluorouracil by stabilizing the ternary complex between fluorodeoxymonophosphate, thymidylate synthase, and the cofactor. Used for Colorectal cancer (in combination with 5-fluorouracil), Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}